Last updated: February 17, 2026
Overview
Propoxyphene napsylate, an opioid analgesic, was once a commonly prescribed pain reliever. Market presence declined sharply after regulatory agencies raised safety concerns due to its high overdose risk. Its removal from the U.S. market in 2010 negatively impacted associated pharmaceutical companies and shifted prescribing patterns toward alternative therapies.
Regulatory Actions and Market Impact
In November 2010, the U.S. Food and Drug Administration (FDA) withdrew approval for propoxyphene due to safety issues, including overdose risk and cardiotoxicity linked to its active metabolite, norpropoxyphene [1].
Prior to withdrawal, the drug generated annual sales approximating $70 million in the U.S., primarily through formulations like Darvon and Darvocet, marketed by companies like Eli Lilly (Darrow) and Watson Pharmaceuticals (Darvocet/Norco).
Product sales plummeted following the FDA's decision, with generic formulations ceasing production and pharmacies withdrawing existing supplies.
Market Dynamics
Decline in Prescriptions: The drug's prescribing rates decreased by over 95% post-2010, due to safety concerns and legal liabilities. Alternative opioids such as acetaminophen with codeine or tramadol absorbed market share.
Regulatory Landscape: The FDA's black box warning and subsequent ban led to a complete market exit, creating a vacuum for pain management options that was partly filled by other opioids.
Generic Market: The generic segment, formerly dominant, dissolved following patent expiration and regulatory withdrawal, limiting commercial opportunities.
Financial Trajectory
Pre-2010: The drug contributed modest revenue, peaking in the late 2000s with estimated global sales around $100 million annually, dominated by the U.S. market.
Post-2010: Market absorption evaporated. Manufacturers wrote off remaining inventories and discontinued production. No current formulations of propoxyphene are commercially available.
Company-Specific Impact: Eli Lilly's sales of Darvon and Darvocet declined sharply in 2010. Watson Pharmaceuticals exited the propoxyphene market altogether.
Future Outlook: Given formal withdrawal, there is no path for renewed sales unless new formulations or safer analogues are developed, which remains unlikely due to safety concerns.
Legal and Litigation Factors
Numerous lawsuits alleging injury from propoxyphene led to significant liabilities for manufacturers. Eli Lilly faced multi-million dollar settlements, contributing to overall decline in market valuation and heightened regulatory scrutiny for similar opioids.
Summary
Proprietary formulations of propoxyphene napsylate are no longer available. The market peaked before regulatory removal, with annual sales reaching approximately $70 million, but has since been rendered obsolete. Companies previously holding rights have exited, and the drug's role in pain management has been supplanted by other opioids or non-opioid alternatives.
Key Takeaways
- Propoxyphene napsylate was a low to moderate-dose opioid analgesic with peak annual sales around $70 million pre-2010.
- FDA withdrawal in 2010, prompted by safety concerns, led to complete market removal.
- Prescriptions declined over 95% post-ban, replaced by other pain management drugs.
- Legal liabilities and safety concerns fundamentally eliminated commercial opportunities.
- No current formulations of propoxyphene exist; market presence is effectively null.
FAQs
-
Why was propoxyphene napsylate removed from the market?
Due to safety concerns, including overdose risk and cardiotoxicity linked to its metabolite, resulting in FDA withdrawal in 2010.
-
What was the approximate sales volume of propoxyphene before market removal?
Around $70 million annually in the U.S. prior to 2010.
-
Are there any current formulations of propoxyphene available?
No, all formulations were withdrawn following regulatory action.
-
Did the withdrawal impact related pharmaceutical companies?
Yes, especially Eli Lilly and Watson Pharmaceuticals, which faced losses and exited the market.
-
What alternatives replaced propoxyphene in pain management?
Drugs like acetaminophen with codeine, tramadol, and other opioids or non-opioid analgesics.
References
[1] FDA Drug Safety Communication. (2010). "FDA recommends removal of propoxyphene products from the U.S. market." U.S. Food and Drug Administration.
